Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

The therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process. While this appears pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurana, Arushi, Lin, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lymphoma (JL Muñoz, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873350/
https://www.ncbi.nlm.nih.gov/pubmed/35212892
http://dx.doi.org/10.1007/s11864-021-00920-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873350/
https://www.ncbi.nlm.nih.gov/pubmed/35212892
http://dx.doi.org/10.1007/s11864-021-00920-6

Ejemplares similares